西罗莫司治疗难治或不耐受常规药物的活动性系统性红斑狼疮:单臂开放标签1/2期试验
这项单臂、开放标签1/2期试验纳入对常规药物抵抗或不耐受的活动性系统性红斑狼疮患者,口服西罗莫司12个月。
要点
- 西罗莫司12个月治疗使55%完成治疗者的疾病活动度评分下降。
- 西罗莫司扩增调节性T细胞和CD8+记忆T细胞,抑制IL-4和IL-17产生。
核心结论
- 活动性系统性红斑狼疮患者经西罗莫司治疗12个月,疾病活动度进行性改善,与促炎T细胞谱系纠正相关。
研究设计与样本
- 单臂、开放标签1/2期试验,在美国纽约州立大学上州医科大学进行,纳入43例,40例符合条件,29例完成12个月治疗。
- 患者年龄≥18岁,符合美国风湿病学会11项诊断标准中至少4项,对常规药物抵抗或不耐受。
- 口服西罗莫司起始剂量2 mg/天,调整至治疗范围6-15 ng/mL,疗程12个月。
- 主要疗效终点为BILAG指数和SLEDAI评估的疾病活动度下降,在完成12个月治疗者中评估;安全性在所有至少接受一剂治疗者中分析。
主要发现
- 29例完成治疗者中16例(55%)SLEDAI和BILAG评分下降。
- 西罗莫司扩增CD4+CD25+FoxP3+调节性T细胞和CD8+记忆T细胞,抑制CD4+和CD4-CD8-双阴性T细胞产生IL-4和IL-17;CD8+记忆T细胞在SRI应答者中选择性扩增。
关键数值与推荐
- SLEDAI和BILAG评分下降定义为疗效终点,55%(16/29)完成治疗者达到。
临床怎么用
- 对于常规药物抵抗或不耐受的活动性系统性红斑狼疮患者,西罗莫司可能作为降低疾病活动度和减少泼尼松用量的选择。
- 治疗期间需监测HDL胆固醇、中性粒细胞计数、血红蛋白和血小板计数,但本试验中变化在安全范围。
局限性
- 单臂、开放标签设计,无安慰剂对照,样本量小(29例完成治疗),结论需后续安慰剂对照试验验证。
- 11例(40例中)因不耐受(n=2)或不依从(n=9)中止治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with systemic lupus erythematosus have T-cell dysfunction that has been attributed to the activation of the mammalian target of rapamycin (mTOR). Rapamycin inhibits antigen-induced T-cell proliferation and has been developed as a medication under the generic designation of sirolimus. We assessed safety, tolerance, and efficacy of sirolimus in a prospective, biomarker-driven, open-label clinical trial. METHODS: We did a single-arm, open-label, phase 1/2 trial of sirolimus in patients with active systemic lupus erythematosus disease unresponsive to, or intolerant of, conventional medications at the State University of New York Upstate Medical University (Syracuse, NY, USA). Eligible participants (aged ≥18 years) had active systemic lupus erythematosus fulfilling four or more of 11 diagnostic criteria defined by the American College of Rheumatology. We excluded patients with allergy or intolerance to sirolimus, patients with life-threatening manifestations of systemic lupus erythematosus, proteinuria, a urine protein to creatinine ratio higher than 0·5, anaemia, leucopenia, or thrombocytopenia. Patients received oral sirolimus at a starting dose of 2 mg per day, with dose adjusted according to tolerance and to maintain a therapeutic range of 6-15 ng/mL. Patients were treated with sirolimus for 12 months. Safety outcomes included tolerance as assessed by the occurrence of common side-effects. The primary efficacy endpoint was decrease in disease activity, assessed using the British Isles Lupus Assessment Group (BILAG) index and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Blood samples of 56 matched healthy individuals were obtained as controls for immunobiological outcomes monitored at each visit. The primary efficacy endpoint was assessed in all patients who completed 12 months of treatment, and all patients who received at least one dose of treatment were included in the safety analyses. This trial is registered with ClinicalTrials.gov, number NCT00779194. FINDINGS: Between March 9, 2009, and Dec 8, 2014, 43 patients were enrolled, three of whom did not meet eligibility criteria. 11 of the 40 eligible patients discontinued study treatment because of intolerance (n=2) or non-compliance (n=9). SLEDAI and BILAG disease activity scores were reduced during 12 months of treatment in 16 (55%) of 29 patients who completed treatment. Mean SLEDAI score decreased from 10·2 (SD 5·6) at enrolment to 4·8 (4·5) after 12 months of treatment (p<0·001) and the mean total BILAG index score decreased from 28·4 (12·4) at enrolment to 17·4 (10·7) after 12 months of treatment (p<0·001). The mean daily dose of prednisone required to control disease activity decreased from 23·7 mg (SD 9·6) to 7·2 mg (2·3; p<0·001) after 12 months of treatment. Sirolimus expanded CD4+CD25+FoxP3+ regulatory T cells and CD8+ memory T-cell populations and inhibited interleukin-4 and interleukin-17 production by CD4+ and CD4-CD8- double-negative T cells after 12 months. CD8+ memory T cells were selectively expanded in SRI-responders. Patient liver function and lymphocyte counts were unchanged. Although HDL-cholesterol (Z=-2·50, p=0·012), neutrophil counts (Z=-1·92, p=0·054), and haemoglobin (Z=-2·83, p=0·005) were moderately reduced during treatment, all changes occurred within a range that was considered safe. Platelet counts were slightly elevated during treatment (Z=2·06, p=0·0400). INTERPRETATION: These data show that a progressive improvement in disease activity is associated with correction of pro-inflammatory T-cell lineage specification in patients with active systemic lupus erythematosus during 12 months of sirolimus treatment. Follow-up placebo-controlled clinical trials in diverse patient populations are warranted to further define the role of mTOR blockade in treatment of systemic lupus erythematosus. FUNDING: Pfizer, the National Institutes of Health, and the Central New York Community Foundation.
引用
- Lai ZW, Kelly R, Winans T, et al. Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial. Lancet. 2018. PMID: 29551338. doi:10.1016/S0140-6736(18)30485-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。